DexCom, Inc. (DXCM)

DexCom's stock price has fluctuated in the past six months. In March 2025, shares sank 6% after an FDA warning letter regarding manufacturing plants. In March 2024, shares gained almost 10% following FDA approval of Stelo. In February 2025, mixed Q4 2024 results were announced, but analysts remained optimistic. In May 2025, a 15-day G7 system launch was announced for H2 2025 amid strong Q1 revenue growth. In July 2025, an update related to a Class I recall for CGM components was issued.

While specific details on demand seasonality are not provided, DexCom's revenue is primarily derived from CGM system sales, including sensors and transmitters, as well as related software and services. The company's financial health is characterized by consistent revenue growth year over year, showcasing the rising adoption of its CGM products. The launch of new products and expanded coverage can drive significant demand at specific times.

DexCom, Inc. is a medical device company focused on designing, developing, and commercializing continuous glucose monitoring (CGM) systems for individuals with diabetes and healthcare providers. The company's major products include Dexcom G6 and G7 CGM systems, Dexcom Share, Dexcom Real-Time API, Dexcom ONE CGM system, Stelo, associated software and mobile apps, and Dexcom Care.

DexCom distributes its products directly in the U.S., Austria, Canada, Germany, Switzerland, and the UK, and through distributors in other countries across Asia, Europe, Africa, Latin America, and the Middle East. The company is expanding its global footprint and plans to establish its first European manufacturing facility in Athenry, County Galway, Ireland. In 2024, the U.S. accounted for 71.7% of net sales, and international revenues improved by 7% year-over-year in Q1 2025.

DexCom's brand reputation has been influenced by product innovation and expansion, increased customer and prescriber base, and strategic partnerships. However, the FDA warning letter, product recalls, and stock price decline have negatively impacted the brand's reputation. The company's customer base grew by approximately 25% in 2024, reaching 2.8-2.9 million users globally. DexCom also added over 50,000 new physicians to its prescriber base in 2024, broadening its presence in primary care.

DexCom, Inc. has a mixed ownership structure comprising institutional, retail, and individual investors. Institutional investors hold approximately 30.45% to 59.05% of the company's stock, with Vanguard Group Inc and BlackRock, Inc. being the largest shareholders. Lucas is the largest individual DexCom shareholder, owning 0.75% of the company. DXCM insiders have sold more shares than they have bought recently.